Ravulizumab treatment outcomes in patients with Generalized Myasthenia Gravis - MG-ARCADIA
Study identifier:D9281R00004
ClinicalTrials.gov identifier:NCT06909253
EudraCT identifier:N/A
CTIS identifier:N/A
Will Be Recruiting
Official Title
Ravulizumab treatment outcomes in patients with Generalized Myasthenia Gravis (gMG) naive to complement inhibitors. Prospective, multicenter, non-interventional study (MG-ARCADIA).
Medical condition
Myasthenia Gravis, Generalized
Phase
Phase 4
Healthy volunteers
No
Study drug
Ravulizumab
Sex
All
Estimated Enrollment
50
Study type
Observational
Age
18 Years - n/a
Date
Study Start Date: 01 Jul 2025
Estimated Primary Completion Date: 31 Dec 2029
Estimated Study Completion Date: 31 Dec 2029
Study design
Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Mar 2025 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Ravulizumab Open-lable arm with gMG patients who received ravulizumab treatment in the frames of NDP in Poland. | - |
